This special emphasis panel reviews small business applications in the general area of development of therapeutic agents to combat bacterial, viral, fungal, parasitic, and prion infections and disease vectors.
- Development and/or testing of novel anti-infective agents or therapeutic processes to fight infective agents using culture systems or animal models
- Investigation of antibodies and therapeutics directly targeting the immune response against microorganisms
- Development of traps, biocides or pesticides active against infectious disease vectors
- Development of processes to optimize industrial production of anti-infective agents
- Development of novel formulations and/or delivery devices for anti-infective agents
Shared Interests and Overlaps:
There are shared interests with Microbial Diagnostics and Detection of Infectious Agents, Food and Waterborne Pathogens, and Methods in Microbial Sterilization, Disinfection and Bioremediation [DCAI (13)] in the advancement of anti-infective approaches. Small business applications addressing the development of agents or methods to detect or combat biofilms in vivo and on medical devices may be reviewed in DCAI (13), whereas applications that seek to develop antibiotic agents that include effectiveness in the context of biofilms may be reviewed here.
There are shared interests with Applied Immunology and Vaccine Development [DCAI (10)] in the development of immunotherapies targeting infectious diseases. Small business applications where the emphasis is on late-stage immunotherapeutic development, such as evaluating efficacy or optimizing production, may be reviewed here, whereas early-stage applications where the emphasis is on basic immunology or conceptual design may be reviewed in DCAI (11).
There are shared interests with Biological Chemistry, Biophysics, and Assay Development [MCST (10)] in the area of assay development. Small business applications addressing fundamental assay development or disease-agnostic assays may be reviewed in MCST (10). Applications focused on the microbiology may be reviewed here.
There are shared interests with Drug Discovery and Development [MBBC (10)] in the advancement of anti-infective approaches. Small business applications that address the development of synthetic small molecules and natural products or address large-scale synthesis for the manufacture of antimicrobial drugs, or seek to advance computational approaches to the discovery of antimicrobial agents, or advance assay development and screening techniques to support antimicrobial development may be reviewed in MBBC (10). Applications that screen small molecule libraries for anti-infective activity may be reviewed here.
There are shared interests with Computational, Modeling, and Biodata Management [MCST (14)] in the advancement of anti-infective approaches. Small business applications that address computational modeling, image processing and systems biology approaches for antimicrobial drug development may be reviewed in MCST (14) if the focus is on the development of the technology. Applications that focus on the utilization of the technology for drug development may be reviewed here.